These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 34853102)

  • 21. Effects of Lysulin™ supplementation on pre-diabetes: study protocol for a randomized controlled trial.
    Ranasinghe P; Jayawardena R; Chandrasena L; Noetzel V; Burd J
    Trials; 2019 Mar; 20(1):171. PubMed ID: 30885259
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Study protocol: a multicentre, open-label, parallel-group, phase 2, randomised controlled trial of autologous macrophage therapy for liver cirrhosis (MATCH).
    Brennan PN; MacMillan M; Manship T; Moroni F; Glover A; Graham C; Semple S; Morris DM; Fraser AR; Pass C; McGowan NWA; Turner ML; Lachlan N; Dillon JF; Campbell JDM; Fallowfield JA; Forbes SJ
    BMJ Open; 2021 Nov; 11(11):e053190. PubMed ID: 34750149
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Experiences of the Data Monitoring Committee for the RECOVERY trial, a large-scale adaptive platform randomised trial of treatments for patients hospitalised with COVID-19.
    Sandercock PAG; Darbyshire J; DeMets D; Fowler R; Lalloo DG; Munavvar M; Staplin N; Warris A; Wittes J; Emberson JR
    Trials; 2022 Oct; 23(1):881. PubMed ID: 36258219
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BOND study: a randomised double-blind, placebo-controlled trial over 12 months to assess the effects of benfotiamine on morphometric, neurophysiological and clinical measures in patients with type 2 diabetes with symptomatic polyneuropathy.
    Bönhof GJ; Sipola G; Strom A; Herder C; Strassburger K; Knebel B; Reule C; Wollmann JC; Icks A; Al-Hasani H; Roden M; Kuss O; Ziegler D
    BMJ Open; 2022 Feb; 12(2):e057142. PubMed ID: 35115359
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Equipoise, standard of care and consent: responding to the authorisation of new COVID-19 treatments in randomised controlled trials.
    Holm S; Lewis J; Dal-Ré R
    J Med Ethics; 2023 Jul; 49(7):465-470. PubMed ID: 35606010
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomized Controlled Trial Evaluating the Benefit of a Novel Clinical Decision Support System for the Management of COVID-19 Patients in Home Quarantine: A Study Protocol.
    Alcoceba-Herrero I; Coco-Martín MB; Leal-Vega L; Martín-Gutiérrez A; Peña-de Diego L; Dueñas-Gutiérrez C; de Castro-Rodríguez F; Royuela-Ruiz P; Arenillas-Lara JF
    Int J Environ Res Public Health; 2023 Jan; 20(3):. PubMed ID: 36767667
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapies for Long COVID in non-hospitalised individuals: from symptoms, patient-reported outcomes and immunology to targeted therapies (The TLC Study).
    Haroon S; Nirantharakumar K; Hughes SE; Subramanian A; Aiyegbusi OL; Davies EH; Myles P; Williams T; Turner G; Chandan JS; McMullan C; Lord J; Wraith DC; McGee K; Denniston AK; Taverner T; Jackson LJ; Sapey E; Gkoutos G; Gokhale K; Leggett E; Iles C; Frost C; McNamara G; Bamford A; Marshall T; Zemedikun DT; Price G; Marwaha S; Simms-Williams N; Brown K; Walker A; Jones K; Matthews K; Camaradou J; Saint-Cricq M; Kumar S; Alder Y; Stanton DE; Agyen L; Baber M; Blaize H; Calvert M
    BMJ Open; 2022 Apr; 12(4):e060413. PubMed ID: 35473737
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Can process mining automatically describe care pathways of patients with long-term conditions in UK primary care? A study protocol.
    Litchfield I; Hoye C; Shukla D; Backman R; Turner A; Lee M; Weber P
    BMJ Open; 2018 Dec; 8(12):e019947. PubMed ID: 30518578
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The B-MaP-C study: Breast cancer management pathways during the COVID-19 pandemic. Study protocol.
    Courtney A; O'Connell R; Rattay T; Kim B; Cutress RI; Kirwan CC; Gandhi A; Fairbrother P; Sharma N; Cartlidge CWJ; Horgan K; McIntosh SA; Leff DR; Vidya R; Potter S; Holcombe C; Copson E; Coles CE; Dave RV
    Int J Surg Protoc; 2020; 24():1-5. PubMed ID: 32838092
    [TBL] [Abstract][Full Text] [Related]  

  • 30. INNODIA Master Protocol for the evaluation of investigational medicinal products in children, adolescents and adults with newly diagnosed type 1 diabetes.
    Dunger DB; Bruggraber SFA; Mander AP; Marcovecchio ML; Tree T; Chmura PJ; Knip M; Schulte AM; Mathieu C;
    Trials; 2022 May; 23(1):414. PubMed ID: 35585600
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anticipate study protocol: Baseline profile and care outcomes of patients attending Mater Misericordiae University Hospital with COVID-19 infection.
    Avramovic G; McHugh T; Connolly SP; Cullen W; Lambert JS
    HRB Open Res; 2020; 3():52. PubMed ID: 33655196
    [No Abstract]   [Full Text] [Related]  

  • 32. Infrastructure and operating processes of PIONEER, the HDR-UK Data Hub in Acute Care and the workings of the Data Trust Committee: a protocol paper.
    Gallier S; Price G; Pandya H; McCarmack G; James C; Ruane B; Forty L; Crosby BL; Atkin C; Evans R; Dunn KW; Marston E; Crawford C; Levermore M; Modhwadia S; Attwood J; Perks S; Doal R; Gkoutos G; Dormer R; Rosser A; Fanning H; Sapey E
    BMJ Health Care Inform; 2021 Apr; 28(1):. PubMed ID: 33849921
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical outcomes of the AdaptResponse trial.
    Komamura K; Iwase M
    Lancet; 2024 Jun; 403(10443):2484. PubMed ID: 38851282
    [No Abstract]   [Full Text] [Related]  

  • 34. Lessons From a Negative Clinical Trial: Novel Immunological Targets for COVID-19 and Beyond.
    Sullivan KM; Matthay MA
    Crit Care Med; 2023 Jan; 51(1):153-156. PubMed ID: 36519993
    [No Abstract]   [Full Text] [Related]  

  • 35. Predictive performance and clinical application of COV50, a urinary proteomic biomarker in early COVID-19 infection: a prospective multicentre cohort study.
    Staessen JA; Wendt R; Yu YL; Kalbitz S; Thijs L; Siwy J; Raad J; Metzger J; Neuhaus B; Papkalla A; von der Leyen H; Mebazaa A; Dudoignon E; Spasovski G; Milenkova M; Canevska-Taneska A; Salgueira Lazo M; Psichogiou M; Rajzer MW; Fuławka Ł; Dzitkowska-Zabielska M; Weiss G; Feldt T; Stegemann M; Normark J; Zoufaly A; Schmiedel S; Seilmaier M; Rumpf B; Banasik M; Krajewska M; Catanese L; Rupprecht HD; Czerwieńska B; Peters B; Nilsson Å; Rothfuss K; Lübbert C; Mischak H; Beige J;
    Lancet Digit Health; 2022 Oct; 4(10):e727-e737. PubMed ID: 36057526
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dorzagliatin in drug-naïve patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial.
    Zhu D; Li X; Ma J; Zeng J; Gan S; Dong X; Yang J; Lin X; Cai H; Song W; Li X; Zhang K; Zhang Q; Lu Y; Bu R; Shao H; Wang G; Yuan G; Ran X; Liao L; Zhao W; Li P; Sun L; Shi L; Jiang Z; Xue Y; Jiang H; Li Q; Li Z; Fu M; Liang Z; Guo L; Liu M; Xu C; Li W; Yu X; Qin G; Yang Z; Su B; Zeng L; Geng H; Shi Y; Zhao Y; Zhang Y; Yang W; Chen L
    Nat Med; 2022 May; 28(5):965-973. PubMed ID: 35551294
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ARCADIA study protocol: a phase II, randomised, double-blind, placebo-controlled clinical trial to assess the safety and efficacy of AZD1656 in patients with diabetes hospitalised with suspected or confirmed COVID-19.
    McCafferty K; Hollowood Z; Allen M; Lockhart D; Chorlton J; Martin J
    BMJ Open; 2021 Dec; 11(12):e049650. PubMed ID: 34853102
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomised, double-blind, placebo-controlled, multicentre clinical trial of AZD1656 in diabetic patients hospitalised with COVID-19: The ARCADIA Trial - implications for therapeutic immune modulation.
    Chorlton J; Hollowood Z; Dyer C; Lockhart D; Boekman P; McCafferty K; Coffey P; Marelli-Berg F; Martin J
    EClinicalMedicine; 2022 Sep; 51():101604. PubMed ID: 35996565
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Using BCG vaccine to enhance non-specific protection of health care workers during the COVID-19 pandemic: A structured summary of a study protocol for a randomised controlled trial in Denmark.
    Madsen AMR; Schaltz-Buchholzer F; Benfield T; Bjerregaard-Andersen M; Dalgaard LS; Dam C; Ditlev SB; Faizi G; Johansen IS; Kofoed PE; Kristensen GS; Loekkegaard ECL; Mogensen CB; Mohamed L; Ostenfeld A; Oedegaard ES; Soerensen MK; Wejse C; Jensen AKG; Nielsen S; Krause TG; Netea MG; Aaby P; Benn CS
    Trials; 2020 Sep; 21(1):799. PubMed ID: 32943115
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dose-ranging study with the glucokinase activator AZD1656 as monotherapy in Japanese patients with type 2 diabetes mellitus.
    Kiyosue A; Hayashi N; Komori H; Leonsson-Zachrisson M; Johnsson E
    Diabetes Obes Metab; 2013 Oct; 15(10):923-30. PubMed ID: 23522182
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.